CH may treat inflammation and prevent fibrosis by decreasing the inflammatory response and fibrosis induced by TGF-β1 in synovial fibroblasts (SFs) via inhibiting thioredoxin-interacting protein (TXNIP)-NLRP3 interactions in TGF-β-induced SFs [51]. The gene discussed is TXNIP; the disease is cyclic hematopoiesis.